Dr. Loretta J. Nastoupil, MD

Dr. Nastoupil practices at Southwest Memorial Hospital in Cortez, Colorado, part of Southwest Health System.

Dr. Nastoupil's NPI, 1407048630, was assigned on August 12, 2007. Dr. Nastoupil graduated from UT Southwestern Medical Center in 2007. Dr. Nastoupil's Texas license number on file is P6877.

Dr. Nastoupil's primary practice is Southwest Memorial Hospital, at 1311 N Mildred Rd, Cortez, CO 81321 in Montezuma County. The practice phone is (970) 565-6666.

Dr. Nastoupil's primary practice is Southwest Memorial Hospital in Cortez, Colorado, part of Southwest Health System. Dr. Nastoupil is also affiliated with San Juan Regional Medical Center. The medical group on file is Cardiac & Thoracic Surgery Associates (CTSA). Dmand AI also links Dr. Nastoupil to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nastoupil practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nastoupil's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nastoupil is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Nastoupil's licenses on file in 12 states: Texas, Florida, Colorado, Arizona, Tennessee, Washington, Alabama, Louisiana, Mississippi, Oklahoma, Georgia and Missouri.

Dmand AI lists chronic anemia, chronic leukemia, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Nastoupil treats.

CMS data shows 653 Medicare services from Dr. Nastoupil across 5 procedure codes in 2024, all of them office visits, for 379 Medicare patients. Medicare paid $41,646 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 379 Medicare patients who saw Dr. Nastoupil in 2024. The largest group is 65 to 74, with 186 patients. 66% of them have high blood pressure, and 66% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nastoupil's median patient age at 73, with 48% women.

In 2024, Dr. Nastoupil wrote 505 Medicare Part D claims for 146 patients. 78% of them were for generic drugs. CMS names the drug for 312 of them, across 12 drugs with 11 or more claims each, at $882,931 in total drug cost. In 2023, CMS named 258 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Nastoupil for performance year 2024, reported as part of a group. Dr. Nastoupil accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nastoupil as offering telehealth.

Dmand AI links 195 papers to Dr. Nastoupil, published from 2011 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Follicular. Dr. Nastoupil has published most often in Blood Adv. Dr. Nastoupil's most frequent co-authors are Sattva S. Neelapu, MD, Jason R. Westin, MD and Luis E. Fayad, MD.

Dmand AI links Dr. Nastoupil to 4 clinical trials. 3 are still active or recruiting. Conditions studied include Lymphoma, Non-Hodgkin, Lymphoma and Lymphoma, B-Cell.

CMS Open Payments shows 406 general payments to Dr. Nastoupil from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Gilead Sciences, Inc. paid the most, $95,452. It also lists 21 research payments totaling $175,720 from 2017 to 2025.

Dr. Nastoupil graduated from UT Southwestern Medical Center in 2007. Dr. Nastoupil is a member of ASCO.

Dr. Nastoupil is in network with 19 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 11. Check the plan with the practice before a visit.